PFKFB3 confers cisplatin resistance in gastric cancer by inhibiting ferroptosis through SLC7A11/xCT dephosphorylation. (PubMed, Int Immunopharmacol) - May 29, 2025 - "The combination of cisplatin and Erastin, a ferroptosis inducer, could synergistically enhance the anti-tumor effect of cisplatin in a subcutaneous tumor mouse model. Our findings demonstrate that PFKFB3 desensitizes gastric cancer to cisplatin by inhibiting ferroptosis through SLC7A11/xCT dephosphorylation, suggesting PFKFB3 inhibition as a potential strategy to overcome cisplatin resistance in GC patients."
Journal • Gastric Cancer • Oncology • Solid Tumor • PFKFB3 • SLC7A11
|
|
Huayang Pan; Jiang Yu; Jiani Wu; Jiaolong Shi; Kai Yang; Sheng Liu; Shuai Xu; Xingxing Yao; Zhanke He; Zhiying Lian
|